search
Back to results

Capsaicin for Cerebral Perfusion Augmentation (CCPA)

Primary Purpose

Cerebral Circulatory Disorder

Status
Completed
Phase
Phase 2
Locations
Mexico
Study Type
Interventional
Intervention
Capsaicin
Sponsored by
Instituto Mexicano del Seguro Social
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Cerebral Circulatory Disorder focused on measuring capsaicin, cerebal perfusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed Informed Consent Form
  • Previous diagnosis and stable condition of one of the following:

Diabetes Mellitus Hypertension Dyslipidemia Chronic Obstructive Pulmonary Disease

Exclusion Criteria:

  • History of alergy or hypersensibility to dietary capsaicin
  • Previous diagnosis of stroke
  • Chronic use of cholinergic/anticholinergic drugs
  • Chronic use of sympathomimetic drugs
  • Chronic use of serotonergic drugs
  • Chronic use of dopaminergic drugs

Sites / Locations

  • Centenario Hospital Miguel Hidalgo

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Capsaicin .66μMol/ml

Capsaicin .99μMol/ml

Arm Description

Group receiving .66μMol/ml

Group receiving .99μMol/ml

Outcomes

Primary Outcome Measures

Mean velocity
The Mean velocity in the Middle Cerebral Artery
Pulsatility Index
A calculated flow parameter in ultrasound, derived from the maximum, minimum, and mean Doppler frequency shifts during a defined cardiac cycle.

Secondary Outcome Measures

Mean arterial pressure (MAP)
The average arterial pressure throughout one cardiac cycle, systole, and diastole.
Cerebral Blood Flow index
The result of the following formula: CBFi = (MAP * 10) / 1.47^Pulsatility Index.

Full Information

First Posted
September 13, 2022
Last Updated
March 11, 2023
Sponsor
Instituto Mexicano del Seguro Social
Collaborators
Centenario Hospital Miguel Hidalgo
search

1. Study Identification

Unique Protocol Identification Number
NCT05543837
Brief Title
Capsaicin for Cerebral Perfusion Augmentation
Acronym
CCPA
Official Title
Effect of Capsaicin on the Augmentation of Cerebral Perfusion. A Phase II Study.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
September 20, 2022 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
February 28, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Mexicano del Seguro Social
Collaborators
Centenario Hospital Miguel Hidalgo

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine the effect of capsaicin upon serial transcranial Doppler (TCD) markers of cerebral blood flow (CBF). Methods Serial TCD testing in 30 participants with cerebrovascular risk factors. Capsaicin doses .66 and .99 μMol. Outcomes: peak systolic and end-diastolic velocities in the middle cerebral artery (MCA), mean velocity (MV), pulsatility index (PI), CBF index, arterial pressure, and perceived pungency (PP) in five minutes intervals up to 20 minutes.
Detailed Description
Subjects The study is expected to enroll 30 participants who will be recruited from the Internal Medicine outpatient clinic. Those willing to participate will be asked to sign the informed consent form (ICF) and will received the assigned dose of capsaicin. Half of the participants in each dose group will receive stimulation on either left or right side of the palate, but TCD measurements will be bilateral. Chemical stimuli From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; solutions with 66 and 99 μMol/ml solutions will be obtained by diluting the stock solution with distilled water. One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers will be let dry. Immediately before application, filter papers will be rehydrated with 1 milliliter of distilled water. The rehydrated filter paper will be applied and will remain stationary on the subject's hemi palate's posterior surface during TCD measurements. Participants will be instructed not to swallow and to avoid touching the paper filter with their tongue for the 20 minutes of the experiment. TCD testing With a TCD device (Philips Sonos 7500®) will include: peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the middle cerebral artery (MCA) through the temporal window of the stimulated side. After a basal recording post stimulation recordings will initiate immediately after stimulation, and will be followed by serial recordings every five minutes and up to 20 minutes. At each time point the systolic pressure (SP), diastolic pressure (DP), and perceived pungency (PP) on a visual analog scale will be recorded. TCD markers of cerebral blood flow From the initial measurements the Mean velocity (MV) = EDV + [(PSVEDV) / 3], pulsatility index (PI) = PSV - EDV / MV, mean arterial pressure (MAP) = ((2 * DP) + SP) / 3 and, the CBF index (CBFi), CBFi = (MAP * 10) / 1.47^PI, will be calculated. Statistical analysis Shapiro Wilkins W-Test for normality. The results of the continuous variables will be described as median (max-min) or mean+/- SD according to distribuition. The categorical variables will be described as tables of absolute and relative frequencies, and the comparisons between the groups of subjects (according to the dose of capsaicin) will be carried out with chi-square tests. To compare the variables studied between the groups of subjects (according to the different doses of capsaicin), Mann-Whitney U-Test/independent samples Student´s T-Test will be used appropriately. For comparisons of the baseline state with the changes recorded over time, various Wilcoxon signed-rank tests will be performed.The relationship between pungency ratings and MV response will be evaluated by Spearman's rho test. The level of statistical significance will be set at 0.05.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Circulatory Disorder
Keywords
capsaicin, cerebal perfusion

7. Study Design

Primary Purpose
Other
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Capsaicin .66μMol/ml
Arm Type
Experimental
Arm Description
Group receiving .66μMol/ml
Arm Title
Capsaicin .99μMol/ml
Arm Type
Experimental
Arm Description
Group receiving .99μMol/ml
Intervention Type
Drug
Intervention Name(s)
Capsaicin
Other Intervention Name(s)
8-Methyl-N-vanillyl-trans-6-nonenamide
Intervention Description
Patients will receive a fixed dose of capsaicin
Primary Outcome Measure Information:
Title
Mean velocity
Description
The Mean velocity in the Middle Cerebral Artery
Time Frame
20 minutes
Title
Pulsatility Index
Description
A calculated flow parameter in ultrasound, derived from the maximum, minimum, and mean Doppler frequency shifts during a defined cardiac cycle.
Time Frame
20 minutes
Secondary Outcome Measure Information:
Title
Mean arterial pressure (MAP)
Description
The average arterial pressure throughout one cardiac cycle, systole, and diastole.
Time Frame
20 minutes
Title
Cerebral Blood Flow index
Description
The result of the following formula: CBFi = (MAP * 10) / 1.47^Pulsatility Index.
Time Frame
20 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed Informed Consent Form Previous diagnosis and stable condition of one of the following: Diabetes Mellitus Hypertension Dyslipidemia Chronic Obstructive Pulmonary Disease Exclusion Criteria: History of alergy or hypersensibility to dietary capsaicin Previous diagnosis of stroke Chronic use of cholinergic/anticholinergic drugs Chronic use of sympathomimetic drugs Chronic use of serotonergic drugs Chronic use of dopaminergic drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan M Marquez-Romero, MD, MSc
Organizational Affiliation
Unidad de Medicina de Alta Especialidad, Torre Medica CMQ
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centenario Hospital Miguel Hidalgo
City
Aguascalientes
ZIP/Postal Code
20259
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared with any qualified investigator upon request to the PI after signing a data use agreement.
IPD Sharing Time Frame
6 months
IPD Sharing Access Criteria
Any qualified investigator in the field

Learn more about this trial

Capsaicin for Cerebral Perfusion Augmentation

We'll reach out to this number within 24 hrs